Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Protein Z: A putative novel biomarker for early detection of ovarian cancer.

Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, Menon U, Jacobs I, Graham RL.

Int J Cancer. 2016 Jun 15;138(12):2984-92. doi: 10.1002/ijc.30020. Epub 2016 Feb 19.

2.

[Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].

Wu WJ, Wang Q, Zhang W, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2016 Jul 25;51(7):515-23. doi: 10.3760/cma.j.issn.0529-567X.2016.07.007. Chinese.

PMID:
27465871
3.

A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.

Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I, Graham RLJ.

Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.

4.

M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.

Będkowska GE, Ławicki S, Gacuta E, Pawłowski P, Szmitkowski M.

J Ovarian Res. 2015 May 3;8:27. doi: 10.1186/s13048-015-0153-3.

5.

Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.

Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM.

PLoS One. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. eCollection 2015.

6.

Novel risk models for early detection and screening of ovarian cancer.

Russell MR, D'Amato A, Graham C, Crosbie EJ, Gentry-Maharaj A, Ryan A, Kalsi JK, Fourkala EO, Dive C, Walker M, Whetton AD, Menon U, Jacobs I, Graham RL.

Oncotarget. 2017 Jan 3;8(1):785-797. doi: 10.18632/oncotarget.13648.

7.
8.

Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.

Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr; AOCS Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5912-5922. doi: 10.1158/1078-0432.CCR-17-0284. Epub 2017 Jun 21.

9.

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.

Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.

J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30.

10.

[Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].

Zhao BB, Yang ZJ, Wang Q, Pan ZM, Zhang W, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):11-19. doi: 10.3760/cma.j.issn.0529-567X.2017.01.005. Chinese.

PMID:
28190310
11.

Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.

Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.

Ginekol Pol. 2015 Feb;86(2):88-93.

PMID:
25807831
12.

Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.

Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S.

Pathol Oncol Res. 2018 Oct;24(4):739-744. doi: 10.1007/s12253-018-0392-x. Epub 2018 Mar 8.

PMID:
29520570
13.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
14.

[Protein levels and its clinical significance of septin-9 and clusterin in peripheral blood of epithelial ovarian cancer patients].

Lyu N, Yao H, Xiao T, Gao Y, Wu L.

Zhonghua Fu Chan Ke Za Zhi. 2015 Sep;50(9):679-84. Chinese.

PMID:
26675395
15.

Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer.

Kim K, Ruhaak LR, Nguyen UT, Taylor SL, Dimapasoc L, Williams C, Stroble C, Ozcan S, Miyamoto S, Lebrilla CB, Leiserowitz GS.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):611-21. doi: 10.1158/1055-9965.EPI-13-1073. Epub 2014 Feb 20.

16.

Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level.

Lyu N, Wang Y, Wang J, Zhang Z, Kong W.

J Cancer Res Ther. 2018 Jun;14(Supplement):S444-S449. doi: 10.4103/0973-1482.181178.

17.

A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.

Zhu T, Gao W, Chen X, Zhang Y, Wu M, Zhang P, Wang S.

Int J Gynecol Cancer. 2017 Jan;27(1):3-10. doi: 10.1097/IGC.0000000000000846.

18.

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.

Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, O'Shannessy DJ, Somers EB, Yasuda M, Sekino T, Fujiwara K.

Int J Cancer. 2016 Apr 15;138(8):1994-2002. doi: 10.1002/ijc.29937. Epub 2015 Dec 15.

19.

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E.

PLoS One. 2016 Oct 31;11(10):e0165609. doi: 10.1371/journal.pone.0165609. eCollection 2016.

20.

HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.

Gislefoss RE, Langseth H, Bolstad N, Nustad K, Mørkrid L.

Int J Gynecol Cancer. 2015 Nov;25(9):1608-15. doi: 10.1097/IGC.0000000000000532.

PMID:
26501436

Supplemental Content

Support Center